HZNP - Horizon Therapeutics Plc Stock Price, Fair Value and News

116.30USD0.00 (0.00%)Market Closed

Market Summary

USD116.300.00

Market Closed

0.00%

HZNP Stock Price

View Fullscreen

HZNP RSI Chart

HZNP Valuation

Market Cap

26.6B

Price/Earnings (Trailing)

60.8

Price/Sales (Trailing)

7.31

EV/EBITDA

25.73

Price/Free Cashflow

27.79

HZNP Price/Sales (Trailing)

HZNP Profitability

EBT Margin

12.18%

Return on Equity

8.25%

Return on Assets

4.71%

Free Cashflow Yield

3.6%

HZNP Fundamentals

HZNP Revenue

Revenue (TTM)

3.6B

Rev. Growth (Yr)

7.82%

Rev. Growth (Qtr)

13.57%

HZNP Earnings

Earnings (TTM)

438.0M

Earnings Growth (Yr)

108.4%

Earnings Growth (Qtr)

132.37%

Breaking Down HZNP Revenue

Last 7 days

0.3%

Last 30 days

11.3%

Last 90 days

12.7%

Trailing 12 Months

84.5%

How does HZNP drawdown profile look like?

HZNP Financial Health

Current Ratio

4.27

Debt/Equity

0.16

Debt/Cashflow

1.22

HZNP Investor Care

Buy Backs (1Y)

0.60%

Diluted EPS (TTM)

1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.6B	3.6B	0	0
2022	3.8B	3.8B	3.7B	3.6B
2021	2.2B	2.6B	3.0B	3.2B
2020	1.4B	1.5B	1.8B	2.2B
2019	1.3B	1.3B	1.3B	1.3B
2018	1.1B	1.1B	1.1B	1.2B
2017	997.3M	1.0B	1.1B	1.1B
2016	848.6M	933.1M	915.3M	981.1M
2015	358.2M	464.9M	616.3M	757.0M
2014	117.2M	172.2M	223.2M	297.0M
2013	24.6M	31.2M	48.0M	74.0M
2012	8.1M	11.3M	18.4M	18.8M
2011	3.5M	4.7M	5.8M	6.9M
2010	0	0	0	2.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Horizon Therapeutics Plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 06, 2023	desjardin michael a.	back to issuer	-14,776,600	116	-126,838	evp, technical operations
Oct 06, 2023	watkins thomas	back to issuer	-12,867,100	116	-110,447	-
Oct 06, 2023	himawan jeff	back to issuer	-4,264,950	116	-36,609	-
Oct 06, 2023	walbert timothy p	back to issuer	-24,236,500	116	-208,039	chairman, president and ceo
Oct 06, 2023	witz pascale	back to issuer	-2,990,790	116	-25,672	-
Oct 06, 2023	mahony susan	back to issuer	-1,088,690	116	-9,345	-
Oct 06, 2023	grey michael g	back to issuer	-5,595,610	116	-48,031	-
Oct 06, 2023	mcilvenny patrick	back to issuer	-800,821	116	-6,874	chief accounting officer
Oct 06, 2023	watkins thomas	back to issuer	-6,518,520	116	-55,953	-
Oct 06, 2023	daniel william f	back to issuer	-3,718,100	116	-31,915	-

Which funds bought or sold HZNP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	sold off	-100	-1,480	-	-%
Mar 29, 2024	Kapitalo Investimentos Ltda	sold off	-100	-45,048,500	-	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-4,628	-	-%
Mar 27, 2024	NOMURA HOLDINGS INC	sold off	-100	-28,922,500	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-512,390	-	-%
Mar 21, 2024	HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	sold off	-100	-30,575,400	-	-%
Mar 11, 2024	Wahed Invest LLC	sold off	-100	-405,262	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-2,497,450,000	-	-%
Mar 01, 2024	ROYAL LONDON ASSET MANAGEMENT LTD	sold off	-100	-9,605,420	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-80,793,300	-	-%

Are Funds Buying or Selling HZNP?

Are funds buying HZNP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HZNP

No. of Funds

Unveiling Horizon Therapeutics Plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	9.37%	21,236,103	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 07, 2023	blackrock inc.	6.5%	14,794,254	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 03, 2022	blackrock inc.	5.7%	13,008,024	SC 13G/A
Feb 11, 2021	renaissance technologies llc	3.08%	6,798,963	SC 13G/A
Feb 10, 2021	vanguard group inc	9.03%	19,920,258	SC 13G/A
Feb 08, 2021	fmr llc	-	0	SC 13G
Jan 29, 2021	blackrock inc.	6.4%	14,206,978	SC 13G/A
Feb 12, 2020	vanguard group inc	9.12%	17,089,414	SC 13G/A

Horizon Therapeutics Plc News

Latest updates

Horizon Therapeutics Plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	13.6%	945	832	942	925	876	885	1,014	1,037	833	342	745	636	463	356	364	335	321	280	356	325	303
Gross Profit	16.3%	725	623	701	691	646	670	773	785	632	242	583	485	341	258	269	246	231	192	257	234	211
Operating Expenses	-0.9%	582	588	527	531	558	476	540	454	493	402	343	256	303	275	214	197	206	194	174	172	201
S&GA Expenses	-4.2%	434	453	373	398	398	373	399	360	355	332	277	226	222	248	185	172	167	172	175	162	177
R&D Expenses	11.8%	150	134	118	114	103	103	80.00	90.00	140	58.00	-9.48	30.00	81.00	27.00	29.00	25.00	28.00	22.00	20.00	21.00	24.00
EBITDA Margin	7.7%	0.27*	0.25*	0.28*	0.29*	0.32*	0.34*	0.28*	0.30*	0.29*	0.27*	0.33*	0.29*	-	-	-	-	-	-	-	-	-
Interest Expenses	-28.7%	31.00	44.00	27.00	38.00	14.00	28.00	12.00	30.00	13.00	19.00	3.00	19.00	3.00	27.00	6.00	22.00	34.00	16.00	45.00	12.00	40.00
Income Taxes	123.1%	8.00	-35.48	34.00	-0.76	4.00	-31.52	38.00	-19.30	-42.48	-47.75	39.00	-91.08	83.00	-19.03	-555	-30.56	-4.87	-1.92	-49.05	-1.27	5.00
Earnings Before Taxes	604.4%	135	19.00	154	135	65.00	173	211	307	116	-171	230	202	3.00	-32.62	37.00	-12.33	-9.99	-34.78	53.00	32.00	-20.13
EBT Margin	16.6%	0.12*	0.10*	0.15*	0.16*	0.20*	0.21*	0.14*	0.16*	0.15*	0.12*	0.18*	0.11*	-	-	-	-	-	-	-	-	-
Net Income	132.4%	127	55.00	120	136	61.00	204	173	327	158	-123	191	293	-80.01	-13.59	593	18.00	-5.12	-32.86	102	33.00	-24.75
Net Income Margin	15.6%	0.12*	0.10*	0.14*	0.16*	0.20*	0.23*	0.17*	0.19*	0.20*	0.13*	0.18*	0.44*	-	-	-	-	-	-	-	-	-
Free Cashflow	129.9%	143	62.00	402	352	239	202	522	384	75.00	-22.06	373	95.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	3.4%	9,299	8,993	9,115	9,028	8,853	8,740	8,678	8,609	8,207	7,847	6,073	5,767	4,538	4,315	4,436	3,721	3,708	3,936	3,942	4,019	3,990
Current Assets	8.9%	3,922	3,603	3,653	3,412	3,203	2,948	2,800	2,414	2,175	1,831	3,070	2,732	1,489	1,414	1,686	1,479	1,402	1,560	1,546	1,339	1,235
Cash Equivalents	6.6%	2,465	2,312	2,353	2,131	1,893	1,643	1,580	1,069	812	812	2,080	1,725	718	755	1,076	884	866	1,033	959	807	710
Inventory	3.5%	170	164	170	190	204	227	152	237	259	238	75.00	77.00	66.00	68.00	54.00	59.00	51.00	52.00	51.00	53.00	50.00
Net PPE	1.8%	362	356	341	318	302	295	292	286	220	202	189	156	139	142	30.00	26.00	25.00	22.00	20.00	17.00	18.00
Goodwill	0%	1,011	1,011	1,011	1,011	1,011	1,067	1,067	1,069	1,069	663	414	414	414	414	414	414	414	414	414	426	426
Current Liabilities	3.7%	918	885	949	861	791	825	887	854	853	774	876	784	985	592	723	636	637	895	709	692	726
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	250	-	-	-
Shareholder's Equity	4.2%	5,311	5,096	5,072	5,034	4,946	4,818	4,672	4,450	4,074	3,855	4,025	3,797	2,362	2,188	2,185	1,556	1,521	1,504	1,190	1,051	987
Retained Earnings	19.7%	772	645	590	606	584	523	319	145	-181	-339	-215	-406	-699	-619	-605	-1,198	-1,216	-1,211	-1,178	-1,414	-1,440
Additional Paid-In Capital	1.6%	4,522	4,449	4,474	4,425	4,381	4,315	4,373	4,311	4,260	4,200	4,246	4,209	3,068	2,814	2,798	2,761	2,744	2,722	2,375	2,338	2,307
Shares Outstanding	0.2%	229	229	227	229	230	229	227	226	225	224	204	212	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	18,300	-	-	-	20,900	-	-	-	11,000	-	-	-	4,500	-	-	-	2,700

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	87.0%	161	86.00	426	366	249	216	539	411	89.00	-3.73	410	109	100	-62.59	191	88.00	91.00	56.00	109	85.00	62.00
Share Based Compensation	3.7%	60.00	58.00	45.00	45.00	45.00	47.00	49.00	55.00	54.00	61.00	33.00	30.00	27.00	56.00	24.00	18.00	21.00	28.00	28.00	28.00	31.00
Cashflow From Investing	52.0%	-20.03	-41.75	-49.07	-32.02	-12.18	-40.72	-36.84	-142	-85.66	-2,729	-65.43	-22.37	-158	-218	-12.53	-4.47	1.00	-1.85	31.00	9.00	-0.10
Cashflow From Financing	110.3%	9.00	-88.13	-160	-94.37	17.00	-110	10.00	-8.26	-0.53	1,469	4.00	920	20.00	-39.61	12.00	-63.81	-259	21.00	10.00	2.00	-23.82
Buy Backs	-	-	-	162	113	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

HZNP Income Statement

2023-06-30

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net sales	$ 944,959,000	$ 876,411,000	$ 1,777,018,000	$ 1,761,656,000
Cost of goods sold	219,958,000	230,216,000	428,521,000	445,278,000
Gross profit	725,001,000	646,195,000	1,348,497,000	1,316,378,000
OPERATING EXPENSES:
Research and development	150,035,000	103,246,000	284,183,000	206,378,000
Selling, general and administrative	434,125,000	398,221,000	887,479,000	770,955,000
Impairment of goodwill	0	56,171,000	0	56,171,000
Gain on sale of asset	(2,000,000)		(2,000,000)
Total operating expenses	582,160,000	557,638,000	1,169,662,000	1,033,504,000
Operating income	142,841,000	88,557,000	178,835,000	282,874,000
OTHER EXPENSE, NET:
Interest expense, net	(12,098,000)	(21,409,000)	(27,638,000)	(42,665,000)
Foreign exchange gain	326,000	28,000	417,000	448,000
Other income (expense), net	4,183,000	(2,389,000)	2,840,000	(3,131,000)
Total other expense, net	(7,589,000)	(23,770,000)	(24,381,000)	(45,348,000)
Income before expense (benefit) for income taxes	135,252,000	64,787,000	154,454,000	237,526,000
Expense (benefit) for income taxes	8,181,000	3,813,000	(27,301,000)	(27,709,000)
Net income	$ 127,071,000	$ 60,974,000	$ 181,755,000	$ 265,235,000
Net income per ordinary share—basic	$ 0.56	$ 0.27	$ 0.80	$ 1.16
Weighted average ordinary shares outstanding—basic	228,743,143	230,020,004	228,571,356	229,559,715
Net income per ordinary share—diluted	$ 0.54	$ 0.26	$ 0.78	$ 1.12
Weighted average ordinary shares outstanding—diluted	233,935,591	236,166,384	233,938,149	236,077,147
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX
Foreign currency translation adjustments	$ 1,409,000	$ (1,433,000)	$ 794,000	$ (1,893,000)
Pension and other post-employment benefit plan remeasurements	179,000	(547,000)	2,003,000	(222,000)
Interest rate swap contracts designated as cash flow hedges	13,339,000	2,011,000	6,287,000	2,011,000
Other comprehensive income (loss)	14,927,000	31,000	9,084,000	(104,000)
Comprehensive income	$ 141,998,000	$ 61,005,000	$ 190,839,000	$ 265,131,000

HZNP Balance Sheet

2023-06-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 2,464,623	$ 2,352,833
Restricted cash	4,791	4,755
Accounts receivable, net	717,417	676,347
Inventories, net	170,325	169,559
Prepaid expenses and other current assets	564,808	449,349
Total current assets	3,921,964	3,652,843
Property, plant and equipment, net	362,326	340,509
Developed technology and other intangible assets, net	2,486,565	2,664,777
In-process research and development	810,000	810,000
Goodwill	1,010,538	1,010,538
Deferred tax assets, net	444,306	431,814
Other long-term assets	263,042	204,135
Total assets	9,298,741	9,114,616
CURRENT LIABILITIES:
Accounts payable	85,543	155,800
Accrued expenses and other current liabilities	496,669	457,557
Accrued trade discounts and rebates	319,469	319,780
Long-term debt-current portion	16,000	16,000
Total current liabilities	917,681	949,137
LONG-TERM LIABILITIES:
Long-term debt, net	2,541,458	2,546,837
Deferred tax liabilities, net	264,815	342,017
Other long-term liabilities	263,828	204,451
Total long-term liabilities	3,070,101	3,093,305
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively	23	23
Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022	(4,585)	(4,585)
Additional paid-in capital	4,522,145	4,474,199
Accumulated other comprehensive income	21,612	12,528
Retained earnings	771,764	590,009
Total shareholders’ equity	5,310,959	5,072,174
Total liabilities and shareholders' equity	$ 9,298,741	$ 9,114,616

About Horizon Therapeutics Plc

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

CEO	Mr. Timothy P. Walbert
WEBSITE	horizontherapeutics.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	2190

Horizon Therapeutics Plc Frequently Asked Questions

What is the ticker symbol for Horizon Therapeutics Plc? What does HZNP stand for in stocks?

HZNP is the stock ticker symbol of Horizon Therapeutics Plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Horizon Therapeutics Plc (HZNP)?

As of Wed Apr 03 2024, market cap of Horizon Therapeutics Plc is 26.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HZNP stock?

You can check HZNP's fair value in chart for subscribers.

What is the fair value of HZNP stock?

You can check HZNP's fair value in chart for subscribers. The fair value of Horizon Therapeutics Plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Horizon Therapeutics Plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HZNP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Horizon Therapeutics Plc a good stock to buy?

The fair value guage provides a quick view whether HZNP is over valued or under valued. Whether Horizon Therapeutics Plc is cheap or expensive depends on the assumptions which impact Horizon Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HZNP.

What is Horizon Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 03 2024, HZNP's PE ratio (Price to Earnings) is 60.8 and Price to Sales (PS) ratio is 7.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HZNP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Horizon Therapeutics Plc's stock?

In the past 10 years, Horizon Therapeutics Plc has provided 0.422 (multiply by 100 for percentage) rate of return.